Drug class
Alpha-Beta Blockers
Alpha-beta blockers, also designated as combined alpha- and beta-adrenergic receptor antagonists or vasodilating third-generation beta-blockers, are cardiovascular medications that competitively inhibit both alpha-1 and beta-adrenergic receptors. Read more about Alpha-Beta Blockers
77 drugs in this class 57 manufacturers
Drugs in Alpha-Beta Blockers
CARVEDILOL
LABETALOL HCL
CARVEDILOL ER (carvedilol phosphate)
LABETALOL HCL
LABETALOL HCL
LABETALOL HCL
CARVEDILOL
LABETALOL HCL
Alpha-beta blockers, also designated as combined alpha- and beta-adrenergic receptor antagonists or vasodilating third-generation beta-blockers, are cardiovascular medications that competitively inhibit both alpha-1 and beta-adrenergic receptors.
By concurrently blocking beta receptors in the myocardium and alpha-1 receptors on vascular smooth muscle, these agents decrease myocardial contractility, heart rate, and systemic vascular resistance while avoiding the unopposed reflex vasoconstriction often observed with traditional nonselective beta blockade.
Clinically represented by agents such as carvedilol and labetalol, this drug class is primarily indicated for managing essential hypertension, hypertensive emergencies, chronic heart failure with reduced ejection fraction, and left ventricular dysfunction following myocardial infarction.
-
nih.gov
Alpha-beta blockers, also designated as combined alpha- and beta-adrenergic receptor antagonists or vasodilating third-generation beta-blockers, are cardiovascular medications that competitively inhibit both alpha-1 and beta-adrenergic receptors Clinically represented by agents such as carvedilol and labetalol, this drug class is primarily indicated for managing essential hypertension, hypertensive emergencies, chronic heart failure with reduced ejection fraction, and left ventricular dysfunctio...
-
nih.gov
Alpha-beta blockers, also designated as combined alpha- and beta-adrenergic receptor antagonists or vasodilating third-generation beta-blockers, are cardiovascular medications that competitively inhibit both alpha-1 and beta-adrenergic receptors
-
fda.gov
By concurrently blocking beta receptors in the myocardium and alpha-1 receptors on vascular smooth muscle, these agents decrease myocardial contractility, heart rate, and systemic vascular resistance while avoiding the unopposed reflex vasoconstriction often observed with traditional nonselective beta blockade
-
fda.gov
By concurrently blocking beta receptors in the myocardium and alpha-1 receptors on vascular smooth muscle, these agents decrease myocardial contractility, heart rate, and systemic vascular resistance while avoiding the unopposed reflex vasoconstriction often observed with traditional nonselective beta blockade
-
nih.gov
By concurrently blocking beta receptors in the myocardium and alpha-1 receptors on vascular smooth muscle, these agents decrease myocardial contractility, heart rate, and systemic vascular resistance while avoiding the unopposed reflex vasoconstriction often observed with traditional nonselective beta blockade
-
goodrx.com
Clinically represented by agents such as carvedilol and labetalol, this drug class is primarily indicated for managing essential hypertension, hypertensive emergencies, chronic heart failure with reduced ejection fraction, and left ventricular dysfunction following myocardial infarction
-
nih.gov
Clinically represented by agents such as carvedilol and labetalol, this drug class is primarily indicated for managing essential hypertension, hypertensive emergencies, chronic heart failure with reduced ejection fraction, and left ventricular dysfunction following myocardial infarction
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.